Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POSIBIL6ESKD clazakizumab dose-finding and cardiovascular outcomes study in dialysis-dependent end stage kidney disease
2022-500273-14-00Phase 3Authorised
- Sponsor
- CSL Behring
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of clazakizumab in chronic kidney disease (CKD) (4 arms), sponsored by CSL Behring. Primary endpoints: Change from baseline in log-transformed hs-CRP and Time to first cardiovascular death or myocardial infarction. Planned start Jul 2023; status: authorised.
02
Drugs
clazakizumab
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-500273-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500273-14-00.